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Point prevalence surveys of healthcare-associated 
infections (HAI) and antimicrobial use in the European 
Union and European Economic Area (EU/EEA) from 
2016 to 2017 included 310,755 patients from 1,209 
acute care hospitals (ACH) in 28 countries and 117,138 
residents from 2,221 long-term care facilities (LTCF) 
in 23 countries. After national validation, we esti-
mated that 6.5% (cumulative 95% confidence inter-
val (cCI): 5.4–7.8%) patients in ACH and 3.9% (95% 
cCI: 2.4–6.0%) residents in LTCF had at least one HAI 
(country-weighted prevalence). On any given day, 
98,166 patients (95% cCI: 81,022–117,484) in ACH and 
129,940 (95% cCI: 79,570–197,625) residents in LTCF 
had an HAI. HAI episodes per year were estimated at 
8.9 million (95% cCI: 4.6–15.6 million), including 4.5 
million (95% cCI: 2.6–7.6 million) in ACH and 4.4 mil-
lion (95% cCI: 2.0–8.0 million) in LTCF; 3.8 million 
(95% cCI: 3.1–4.5 million) patients acquired an HAI 
each year in ACH. Antimicrobial resistance (AMR) to 
selected AMR markers was 31.6% in ACH and 28.0% 
in LTCF. Our study confirmed a high annual number of 
HAI in healthcare facilities in the EU/EEA and indicated 
that AMR in HAI in LTCF may have reached the same 
level as in ACH.
Introduction
In 2016, the European Centre for Disease Prevention 
and Control (ECDC) estimated that the burden of six 
main types of healthcare-associated infection (health-
care-associated pneumonia, urinary tract infection, 
surgical site infection,  Clostridium difficile  infection, 
neonatal sepsis and primary bloodstream infection)) 
expressed in disability-adjusted life years (DALYs) in 
the European Union and European Economic Area (EU/
EEA) was higher than the combined burden of 31 other 
infectious diseases under surveillance by ECDC [1,2]. 
The estimated number of healthcare-associated infec-
tions (HAI) used in the study was based on the data 
of the first ECDC point prevalence survey (PPS) of HAI 
and antimicrobial use in acute care hospitals (ACH) 
from 2011 to 2012 [3] and did not take into account 
HAI occurring in other healthcare facilities. In particu-
lar, ECDC had previously estimated that the number of 
residents with an HAI on any given day in European 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































of magnitude as the number of patients with an HAI on 
any given day in ACH [4-6].
In the period from 2016 to 2017, ECDC organised two 
PPS of HAI and antimicrobial use: the second PPS in 
ACH and the third PPS in LTCF in the EU/EEA. The objec-
tive of the current study was to report on the HAI and 
antimicrobial resistance results of both surveys and 
to estimate the combined total number of HAI on any 
given day and the number of HAI per year from 2016 to 
2017 in the EU/EEA.
Methods
Participation of countries
All EU/EEA countries and EU candidate and poten-
tial candidate countries were invited to organise a 
national PPS in ACH and LCTF in their country in any of 
four periods (April to June or September to November 
of 2016 or 2017). For reasons of feasibility at national 
level, the PPS in ACH and LCTF could be organised 
during different periods. Data were collected accord-
ing to two specific standardised ECDC protocols [7,8]. 
All countries used the ECDC protocols and included 
all HAI types except for one country (Norway) for ACH 
and four countries (France, the Netherlands, Norway 
and Sweden) for LCTF. Norway used national protocols 
with the same case definitions as in the ECDC proto-
cols, but provided fewer details and did not require the 
inclusion of all types of HAI. LTCF data from France and 
the Netherlands were also collected using national pro-
tocols not including all types of HAI. LTCF protocols in 
France, the Netherlands and Norway all included uri-
nary tract infections, lower respiratory tract infections 
and skin infections, in addition other HAI types vary-
ing by country. Surveys in separate healthcare admin-
istrations in the United Kingdom (UK), i.e. England, 
Northern Ireland, Scotland and Wales, were organised 
independently and results were reported separately.
Selection of participating facilities and patients
It was recommended that countries selected the par-
ticipating ACH and LCTF by systematic random sam-
pling from national lists ranked by type and size to 
ensure optimal country representativeness. For each 
country, the required sample size was calculated for 
an estimated prevalence of 6% for ACH and 4% for 
LCTF, based on the results of the previous PPS [3,6], 
with an absolute precision of 1%. Representativeness 
was categorised as optimal, good, poor or very poor, 
depending on the sampling method of the facilities, the 
number of included patients/residents and the number 
of included facilities [7,8]. For example, ‘optimal repre-
sentativeness’ meant that the country performed sys-
tematic sampling of at least 25 healthcare facilities or 
included at least 75% of all facilities or beds at national 
level, and achieved the recommended sample size.
For ACH, the protocol recommended that data from a 
single ward should be collected on one single day and 
that the time frame for data collection for all wards of 
a single hospital would not exceed 3 weeks. For LCTF, 
it was recommended to collect data on a single day, 
except for larger LCTF.
We included all patients/residents present on the hos-
pital ward or LTCF at 8:00 on the day of the PPS and 
still present at the time of day when the PPS was per-
formed. In addition, LTCF residents needed to be full-
time residents (i.e. living 24 hours a day in the LTCF). 
Patients/residents who were temporarily absent from 
their room, e.g. for diagnostic procedures, had to be 
included.
Case definitions
Case definitions for HAI differed for ACH and for LCTF, 
reflecting differences in access to diagnostic methods 
between the two settings, as well as the specific signs 
and symptoms of infection in elderly LTCF residents 
[7,8]. For both PPS, an HAI was defined as active on the 
day of the PPS when signs and symptoms were present 
on the date of the PPS, or when signs and symptoms 
were no longer present but the patient/resident was 
still receiving treatment for that infection on the date 
of the PPS. HAI present on admission were included 
in both protocols. In the LTCF protocol, HAI associated 
with a stay in any other healthcare facility – another 
LTCF or a hospital – were included. In the ACH proto-
col, however, only HAI imported from other ACH were 
included, excluding HAI present on admission asso-
ciated with a previous LTCF stay. LTCF data in France 
and Sweden did not include HAI imported from other 
healthcare facilities.
Data analysis
Data were analysed with Stata, version 14.1 (StataCorp, 
Texas, United States). The prevalence of HAI was 
expressed as the percentage of patients/residents with 
at least one HAI on the day of the PPS. To account for 
clustering within ACH or LCTF, 95% confidence intervals 
(CI) were calculated using the svy proportion command 
in Stata. Overall weighted prevalence percentages 
were calculated by applying the country-specific preva-
lence on the number of occupied beds in each country 
and summing up the total number of patients with at 
least one HAI for EU/EEA countries. National denomina-
tor data were obtained by questionnaire from national 
survey coordinators, from Eurostat data if national 
denominator data were not submitted [9-11] or from the 
previous PPS if Eurostat data were missing or incom-
plete [3,4,6]. To estimate the total number of HAI or 
patients with at least one HAI for the whole EU/EEA, 
the average results from participating EU/EEA coun-
tries were applied to the national denominator data 
from non-participating EU/EEA countries. For data col-
lected using national protocols which did not include 
all types of HAI, imputation of non-included types of 
HAI was done based on EU/EEA averages to make prev-
alence percentages comparable. In ACH, imputation 
resulted in adding 7.3% (36/495) of patients with HAI 
in Norway. In LCTF, imputation resulted in adding 5.8% 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































in the Netherlands and 7.6% (9/119) in Norway, or 0.8% 
(32/3,780) overall. As these imputations were done for 
the aggregated national results, correction of CI for 
clustering within LCTF could not be applied for these 
countries and binomial exact CI were used instead.
Antimicrobial resistance
Antimicrobial resistance (AMR) in HAI was evalu-
ated using two indicators: a composite index of 
AMR and the percentage of carbapenem-resistant 
Enterobacteriaceae. The composite index of AMR was 
calculated as the percentage of resistant isolates 
for the ‘first level’ AMR markers in the PPS protocols 
divided by the sum of the isolates for which results 
from antimicrobial susceptibility testing (AST) were 
reported. These first level markers were Staphylococcus 
aureus  resistant to meticillin (MRSA),  Enterococcus 
faecium  and  Enterococcus faecalis  resistant to 
vancomycin, Enterobacteriaceae resistant to third-
generation cephalosporins, and  Pseudomonas aer-
uginosa  and  Acinetobacter baumannii  resistant to 
carbapenems. The percentage of resistant isolates was 
not calculated when less than 10 isolates with known 
AST results were reported. The composite index of AMR 
at country level was validated by examining the corre-
lation with the composite AMR index calculated from 
EARS-Net data from 2016, including all components 
of the index except AST results for Enterobacteriaceae 
other than  Escherichia coli  and  Klebsiella pneumo-
niae because they are not included in EARS-Net [12,13]. 
Correlations were analysed using the Spearman cor-
relation coefficient rho and the R-squared (R2) and 
regression coefficient from linear regression.
Prevalence to incidence conversion
Estimates of the total number of HAI and patients 
acquiring at least one HAI per year in ACH were based 
on prevalence to incidence conversion using the Rhame 
and Sudderth formula [14]. Details of the method are 
reported in the ECDC PPS report for 2011 and 2012 [3]. 
In addition, sensitivity analyses of the conversion were 
carried out using a method developed by Willrich et 
al. (personal communication: Niklas Willrich, 24 May 
2018), in which the estimates of the length of stay were 
based on a Grenander estimator for discrete monoto-
nously decreasing distributions [15].
Figure 
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Composite index of AMR (% R isolates), 
EARS-Net 2016
A. Correlation between the composite indices of 
      AMR from the PPS in acute care hospitals, 2016-2017 
      and EARS-Net, 2016 (n = 27 countries)
B. Correlation between the composite indices of  AMR from 
     the PPS in acute care hospitals, 2016-2017 and the PPS in 
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ACH: acute care hospital; AMR: antimicrobial resistance; AT: Austria; BE: Belgium; BG: Bulgaria; CY: Cyprus; CZ: Czech Republic; DE: Germany; 
EARS-Net: European Antimicrobial Resistance Surveillance Network; ECDC: European Centre for Disease Prevention and Control; EE: Estonia; 
EL: Greece; ES: Spain; FI: Finland; FR: France; HALT: Healthcare-associated infections in LTCF project; HR: Croatia; HU: Hungary; IE: Ireland; 
IS: Iceland; IT: Italy; LT: Lithuania; LCTF: long-term care facility; LU: Luxembourg; LV: Latvia; MT: Malta; NL: the Netherlands; NO: Norway; PL: 
Poland; PPS: point prevalence survey; PT: Portugal; RO: Romania; RS: Serbia; SI: Slovenia; SK: Slovakia; UK: United Kingdom.
Composite index of AMR: Staphylococcus aureus resistant to meticillin, Enterococcus faecium and Enterococcus faecalis resistant to 
vancomycin, Enterobacteriaceae resistant to third-generation cephalosporins, Pseudomonas aeruginosa and Acinetobacter baumannii 
resistant to carbapenems; EARS-Net: Enterobacteriaceae other than Escherichia coli and Klebsiella pneumoniae not included. Other species 
represented 32.5% of tested Enterobacteriaceae in ACH. France: percentage non-susceptible (resistant + intermediate) isolates instead of 
percentage resistant isolates. In addition to poor representativeness of participating LCTF in Malta, specimens in these LCTF were known to be 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In LCTF, only the number of HAI could be estimated. As 
LTCF usually are permanent residences, HAI do not pro-
long the length of stay of a resident as they do in ACH. 
Therefore, the incidence of HAI in LCTF per year was 
estimated by multiplying the prevalence by 365 days 
and dividing it by the duration of infection (in days), 
with a correction for an average occupancy of LTCF 
beds of 95%, calculated from institutional denomina-
tor data. The duration of infection was estimated, by 
type of HAI, from the date of onset to the date of the 
PPS, using the median duration of HAI until the day of 
the PPS multiplied by 2.
Validation studies
It was strongly recommended that all participating 
EU/EEA countries perform validation studies of their 
national PPSs. For the PPS in ACH, ECDC also offered 
financial support to national institutions coordinat-
ing PPS so that they could organise validation studies 
with a minimum requirement to re-examine 250 patient 
charts in five ACH. For both the PPS in ACH and that 
in LCTF, the objective was to estimate representative 
validity parameters at the EU/EEA level rather than at 
country level ([16]; ACH validation protocol available 
from the authors on request). Validation studies were 
performed by national validation teams composed of 
members of the national coordination teams, using the 
ECDC HAI case definitions as gold standard. Validation 
results were calculated for each country, by matching 
patients included in the validation sample with their 
corresponding data collected in the primary PPS. The 
percentage of false positives (FP) and false negatives 
(FN) was calculated from the matched analysis and 
applied to the total national database to calculate the 
sensitivity and specificity for each country, as several 
countries selected high prevalence wards for validation 
to improve precision as recommended by the validation 
study protocol. For correction of the EU/EEA prevalence 
of HAI, the EU/EEA mean FN and FP were applied to 
the total number of patients. The validation-corrected 
HAI prevalence was converted using the Rhame and 
Sudderth formula to estimate the corrected HAI inci-
dence and total number of patients in ACH with at least 
one HAI per year in the period 2016 to 2017.
To calculate CI around EU/EEA estimates, the number 
of patients with at least one HAI obtained from the 
lower and upper limits of the country-specific 95% CIs 
were summed up and divided by the total number of 
occupied beds (for prevalence) or the total number of 
discharges (for estimated incidence) in the EU/EEA. 
These ‘cumulative 95% CI’ (95% cCI) therefore reflect 
a larger, more conservative uncertainty than would be 
obtained by calculating 95% CI on the EU/EEA totals, 
which is in accordance with the limitations of the prev-
alence measurement and the uncertainty inherent to 
the conversion of prevalence to incidence.
Results
Point prevalence survey in acute care hospitals
Participation
In total, 1,735 hospitals from 28 EU/EEA countries and 
one EU candidate country (Serbia) participated in the 
second PPS of HAI and antimicrobial use in European 
ACH in the period 2016 to 2017. Counting UK adminis-
trations separately, the country representativeness of 
the sample was optimal in 20 countries, good in 10, and 
poor in two countries. After adjustment for over-repre-
sentation of countries contributing more than 20,000 
patients to the PPS, 325,737 patients from 1,275 ACH 
remained in the final sample. Aggregated results were 
only reported for the EU/EEA, corresponding to 310,755 
patients from 1,209 ACH. The distribution of the type of 
ACH and the percentage of patients requiring intensive 
care by country is shown in Table 1.
Prevalence and estimated incidence of healthcare-
associated infections
A total of 19,626 HAI were reported in 18,287 patients 
with HAI (1.07 HAI per infected patient). The prevalence 
of patients with at least one HAI in the EU/EEA sample 
was 5.9% (country range: 2.9–10.0%; Table 2). The prev-
alence varied between 4.4% (2,177/49,381 patients) in 
primary care hospitals (n = 333) to 7.1% (7,591/104,562 
patients) in tertiary care hospitals (n = 222) and was 
highest in patients admitted to intensive care units, 
where 19.2% (2,751/14,258) patients had at least one 
HAI compared with 5.2% (15,536/296,397) on average 
for all other specialties combined (Supplement).
When extrapolated to the average daily number of 
occupied beds per country, the weighted HAI preva-
lence was 5.5% (95% cCI: 4.5–6.6%). The weighted 
annual incidence of patients acquiring at least one HAI 
per year in the period 2016 to 2017, estimated using 
prevalence to incidence conversion, was 3.7 (95% cCI: 
2.4–5.3) patients per 100 admissions. National PPS 
validation studies were carried out by 28 countries 
(UK administrations counted separately) in a total of 
236 ACH in the EU/EEA. National validation teams re-
examined 12,228 patient charts independently from 
the primary PPS surveyors. These studies showed that 
on average, 2.3% (country range: 0.3–5.6%) of patients 
who were reported as not having a HAI actually had an 
HAI (false negatives) while one in five (mean: 20.3%, 
country range: 0–46.2%) patients reported as having 
an HAI did not have an HAI (false positives), result-
ing in a mean sensitivity of HAI detection of 69.4% 
(country range: 40.1–94.4%) and a mean specificity of 
98.8% (country range: 96.1–100%). When correcting 
for these results, the adjusted prevalence of patients 
with at least one HAI was estimated at 6.5% (95% cCI: 
5.4–7.8%). Using the Rhame and Sudderth formula to 
convert the latter percentage, the corrected annual inci-
dence was estimated at 4.1 (95% cCI: 3.4–4.9) patients 
per 100 admissions. Applying the EU/EEA averages 
to denominator data from non-participating EU/EEA 
13www.eurosurveillance.org
countries (Denmark and Sweden), this resulted in an 
estimated total of 98,166 (95% cCI: 81,022–117,484) 
patients with at least one HAI on any given day and 
3,758,014 (95% cCI: 3,122,024–4,509,617) patients 
with at least one HAI per year in the period 2016 to 
2017 in ACH in the EU/EEA.
Types of HAI and isolated microorganisms
The most frequently reported types of HAI were res-
piratory tract infections (21.4% pneumonia and 4.3% 
other lower respiratory tract infections), urinary tract 
infections (18.9%), surgical site infections (18.4%), 
bloodstream infections (10.8%) and gastro-intestinal 
infections (8.9%), with C. difficile infections accounting 
for 44.6% of the latter or 4.9% of all HAI. Twenty-three 
per cent of HAI were present on admission. One third 
of HAI on admission were surgical site infections. 
Country-weighted prevalence percentages and 
estimated numbers of HAI per year are shown in Table 
3. After correction for non-participating countries and 
validation, a total of 4.5 million (95% cCI: 2.6–7.6 mil-
lion) HAI were estimated to occur per year in the period 
2016 to 2017 in ACH in the EU/EEA.
A total of 13,085 microorganisms were reported 
in 10,340 (52.7%) HAI. The 10 most fre-
quently isolated microorganisms were  E. 
coli  (16.1%),  S. aureus  (11.6%),  Klebsiella  spp. 
(10.4%),  Enterococcus  spp. (9.7%),  P. aer-
uginosa  (8.0%),  C. difficile  (7.3%), coagulase-
negative staphylococci (7.1%),  Candida  spp. 
(5.2%),  Enterobacter  spp. (4.4%) and  Proteus  spp. 
(3.8%).
Antimicrobial resistance in healthcare-associated 
infections and correlation with EARS-Net data
AST data were available for 8,031 (88.9%) of 9,034 
microorganisms included in the composite index of 
AMR. The index was 31.6% overall (mean of countries: 
30.8%) and varied from 0% in Iceland to 68.9% in 
Romania. The index by country was strongly correlated 
with the index calculated from 2016 EARS-Net data 
on invasive isolates (Spearman’s correlation coeffi-
cient rho: 0.93; p < 0.001; R2: 0.86. Figure) and was on 
average 36% higher for HAI in ACH from the PPS than 
in the EARS-Net data (mean of countries in EARS-Net: 
20.3%). Carbapenem resistance in Enterobacteriaceae 
was 6.2% overall (mean of countries: 5.9%) and ranged 
from 0% in Estonia, Finland, Iceland, Lithuania and 
UK–Northern Ireland to 43.7% in Greece (Table 4). This 
indicator also correlated well with carbapenem resist-
ance in  E. coliand  K. pneumoniae  in EARS-Net data 
(Spearman’s  rho: 0.76; p < 0.001) and was on average 
45% higher in HAI in ACH from the PPS than in EARS-
Net data (mean of countries in EARS-Net: 2.6%). The 
total number of patients acquiring an HAI with at least 
one resistant microorganism was estimated at 291,067 
(95% cCI: 162,417–504,270) patients for the compos-
ite index of AMR and 31,696 (95% cCI: 14,611–78,205) 
patients for carbapenem-resistant Enterobacteriaceae.
ACH: acute care hospital; AMR: antimicrobial resist-
ance; AT: Austria; BE: Belgium; BG: Bulgaria; CY: Cyprus; 
CZ: Czech Republic; DE: Germany; EARS-Net: European 
Antimicrobial Resistance Surveillance Network; ECDC: 
European Centre for Disease Prevention and Control; 
EE: Estonia; EL: Greece; ES: Spain; FI: Finland; FR: 
France; HALT: Healthcare-associated infections in 
LTCF project; HR: Croatia; HU: Hungary; IE: Ireland; IS: 
Iceland; IT: Italy; LT: Lithuania; LCTF: long-term care 
facility; LU: Luxembourg; LV: Latvia; MT: Malta; NL: the 
Netherlands; NO: Norway; PL: Poland; PPS: point prev-
alence survey; PT: Portugal; RO: Romania; RS: Serbia; 
SI: Slovenia; SK: Slovakia; UK: United Kingdom.
Composite index of AMR:  Staphylococcus 
aureus  resistant to meticillin,  Enterococcus fae-
cium  and  Enterococcus faecalis  resistant to 
vancomycin, Enterobacteriaceae resistant to third-
generation cephalosporins,  Pseudomonas aer-
uginosa  and  Acinetobacter baumannii  resistant to 
carbapenems; EARS-Net: Enterobacteriaceae other 
than  Escherichia coli  and  Klebsiella pneumoniae  not 
included. Other species represented 32.5% of tested 
Enterobacteriaceae in ACH. France: percentage non-
susceptible (resistant + intermediate) isolates instead 
of percentage resistant isolates. In addition to poor 
representativeness of participating LCTF in Malta, 
specimens in these LCTF were known to be taken pre-
dominantly in cases of treatment failure (panel B).
Point prevalence survey in long-term care 
facilities
Participation
In total, 3,062 LCTF from 24 EU/EEA countries and two 
EU candidate countries (Serbia and the former Yugoslav 
Republic of Macedonia) participated in the third PPS 
of HAI and antimicrobial use in European LCTF in the 
period 2016 to 2017. Counting UK administrations 
separately, good or optimal representativeness of the 
national sample was obtained in 18 of 24 EU/EEA coun-
tries. After adjustment for over-representation, 117,138 
residents from 2,221 LCTF were included for analysis. 
The main aggregated results were reported for 80.5% 
of participating LCTF, i.e. general nursing homes 
(n = 1,025), residential homes (n = 176) and mixed LCTF 
(n = 587), corresponding to 102,301 residents and 1,788 
LCTF in EU/EEA countries. The characteristics of LCTF 
and residents by country are shown in Table 1.
Prevalence of healthcare-associated infections
A total of 3,858 HAI were reported in 3,780 residents 
with HAI (1.02 HAI per infected resident). The preva-
lence of residents with at least one HAI was 3.7% 
(country range: 0.9–8.5%). When extrapolated to the 
average number of occupied LTCF beds per country, the 
weighted HAI prevalence in LCTF was 3.6% (95% cCI: 
2.9–4.5%). Validation of the PPS in LCTF was performed 
for 953 residents in 17 LCTF in 10 countries. National 
validation teams found 1.1% (95% CI: 0.5–2.0%) false-
negative residents and 19.6% (95% CI: 9.4–33.9%) 
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false-positive residents, yielding a sensitivity of 73.7% 
and a specificity of 99.2% when applied on the total 
EU/EEA database. The country-weighted, validation-
corrected HAI prevalence was 3.9% (95% cCI: 2.4–
6.0%). Applying the EU/EEA prevalence to denominator 
data from non-participating EU/EEA countries, the total 
number of residents with at least one HAI on any given 
day in EU/EEA LCTF was estimated at 129,940 (95% 
cCI: 79,570–197,625) residents (Table 5).
Types of healthcare-associated infections and isolated 
microorganisms
The most frequently reported types of HAI in LCTF 
were respiratory tract infections (33.2% overall, 3.7% 
pneumonia, 22.0% other lower respiratory tract infec-
tions, 7.2% common cold/pharyngitis, 0.3% influenza), 
urinary tract infections (32.0%) and skin infections 
(21.5%). The majority of the reported HAI (84.7%) were 
associated with the LTCF where the PPS was performed, 
while 7.5% and 1.4% were associated with a hospital or 
another LTCF, respectively. The origin was unknown for 
6.4% of HAI in LCTF. Country-weighted prevalence per-
centages and estimated number of infections per year 
are given by type of HAI in  Table 3. The total number 
of HAI in LCTF in the EU/EEA, after applying EU aver-
ages for non-participating EU/EEA countries and cor-
recting for validation, was estimated at 4.4 million 
(95% cCI: 2.0–8.0 million). Microbiological data in 
LCTF were available for 742 (19.2%) HAI. The 10 most 
frequently isolated bacteria were  E. coli  (30.7%),  S. 
aureus  (12.3%),  Klebsiella  spp. (11.4%),  Proteus  spp. 
(10.6%),  P. aeruginosa  (7.1%),  Enterococcus  spp. 
(4.8%),  C. difficile  (4.4%),  Streptococcus  spp. 
(2.8%)  Enterobacter  spp. (2.1%) and coagulase-
negative staphylococci (1.9%).
Antimicrobial resistance in healthcare-associated 
infections and correlation with data from the hospital 
point prevalence survey
AST results were available for 553 (77.6%) of 713 
microorganisms included in the composite index of 
AMR. The index could be calculated for 11 countries 
with at least 10 isolates, and was 28.0% overall, rang-
ing from 6.8% in Finland to 60.0% in Malta (Table 4). 
The composite index of AMR correlated well between 
ACH and LCTF, although Malta was an outlier (Figure, 
Spearman’s  rho  excluding Malta: 0.86; p < 0.001; 
R2 = 0.69). On average, the percentage of resistant 
microorganisms was similar in both settings (regres-
sion coefficient excluding Malta: 1.08). Carbapenem 
resistance in Enterobacteriaceae in LCTF was 4.2% 
overall and did not correlate significantly with the per-
centage in ACH (Table 4).
Discussion
Because both the PPS in ACH and that in LCTF were 
performed during 2016 and 2017, this provided the 
first opportunity to estimate the prevalence, incidence 
and annual number of HAI for ACH and for LCTF in the 
EU/EEA for the same time period. As expected, the 
overall prevalence of HAI was higher in ACH than in 
LCTF, also after correction based on validation study 
results. However, when estimating the total number of 
HAI, both settings were shown to have similarly high 
numbers of HAI annually. In total, 8.9 million distinct 
HAI episodes were estimated to occur annually in ACH 
and LCTF in the EU/EEA. In ACH, where the incidence 
per patient could be calculated, the number of patients 
with at least one HAI was estimated at 3.8 (95% cCI: 
3.1–4.6) million patients per year in the period 2016 to 
2017.
The country-weighted HAI prevalence before valida-
tion correction in ACH of 5.5% (95% cCI: 4.5–6.7%) 
was similar to the HAI prevalence of 5.7% (95% cCI: 
4.5–7.4%) in the ECDC PPS in ACH in the period 2011 
to 2012 [3]. The unweighted HAI prevalence in LCTF of 
3.7% before correction was only slightly higher than 
the prevalence of 3.4% found in the ECDC PPS in LCTF 
in 2013 [6], although imported HAI were included in 
the period 2016 to 2017. The final corrected country-
weighted HAI prevalence estimates of 6.5% in ACH and 
3.9% in LCTF were higher because they were corrected 
for the results of the validation studies, which made 
the current estimates more robust than the previous 
estimates. Similarly, the estimated incidence and num-
ber of HAI in ACH presented in this study were higher 
than the number estimated in the ECDC PPS from 2011 
to 2012 [3] because of the correction for the results 
of the validation study and should therefore not be 
interpreted as an increase for ACH compared with the 
period 2011 to 2012.
The strong correlation of the composite indices of AMR 
in the ECDC PPS in ACH with the EARS-Net data sup-
ports the validity of AMR data collected in the PPSs. 
The 36% higher percentage of resistant isolates in 
HAI in the ECDC PPS was expected given that EARS-
Net only includes data from invasive isolates, i.e. from 
bloodstream infections and meningitides, and that a 
large proportion of isolates reported to EARS-Net are 
from community-associated bloodstream infections, 
especially for MRSA and  E. coli  resistant to third-
generation cephalosporins. However, the fact that the 
composite index of AMR in LCTF was at the same level 
as in ACH, at least in countries where both indicators 
could be calculated, is of concern. Even though the low 
testing frequency in LCTF is probably biased towards 
HAI which are non-responsive to empiric treatment, 
this finding emphasises the urgent need to reinforce 
measures to improve infection prevention and control, 
antimicrobial stewardship as well as microbiological 
laboratory support for LCTF.
Our study has several limitations. Firstly, the small 
number of countries and LCTF that performed validation 
studies in the PPS in LCTF resulted in less robust prev-
alence estimates for LCTF than for ACH, even though 
the LTCF validation results could be used at the EU/
EEA level. Secondly, the conversion from prevalence 
to incidence using the Rhame and Sudderth formula 
has been shown to have several limitations in itself, 
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especially for smaller samples [17,18]. The estimates 
depend on the estimators used, as not all data can 
be acquired from a cross-sectional prevalence study. 
Nevertheless, sensitivity analyses that we performed 
with more recent estimator methodology (personal 
communication: Niklas Willrich, 24 May 2018) [15] 
yielded EU/EEA estimates which were close to those 
reported here, with few exceptions at individual coun-
try level. Especially considering the wide CI, this gave 
more weight to our estimates (Supplement). Thirdly, 
the estimates also strongly depended on the quality of 
the national denominator data of the number of beds, 
and, for ACH, discharges and patient days. Providing 
reliable national denominator data has been shown to 
be difficult for many countries that sometimes provided 
estimates rather than precise numbers, especially for 
LCTF. In addition, as national denominator data for spe-
cialised LCTF were only available in two countries, a 
specific incidence for these types of LTCF could not be 
estimated. In several countries, however, the number 
of beds for these LCTF are included in the total number 
of LTCF beds for the country. We only reported results 
for the main types of LTCF, as these types were con-
sistently included in all countries. Fourthly, the num-
ber of residents with at least one HAI each year could 
not be estimated for LCTF in the EU/EEA. Longitudinal 
HAI incidence data would be required to produce such 
estimates. Fifthly, three countries preferred using their 
national PPS protocols for LCTF and one country for 
ACH, resulting in less robust estimates. Sixthly, the 
total number of HAI with resistant pathogens could 
only be estimated for ACH because of the poor avail-
ability of microbiological results in LCTF. Moreover, 
the annual incidence estimates of HAI with resistant 
pathogens in ACH are underestimated because: (i) in 
almost half of the HAI in ACH, a microorganism was not 
reported, (ii) for 11% of the reported microorganisms, 
AST results were not yet available on the day of the PPS 
and (iii) correction for countries without data and cor-
rection for validation was not performed. Despite these 
limitations, the estimated number of HAI with carbap-
enem-resistant Enterobacteriaceae using Rhame and 
Sudderth conversion in our study (31,696 infections, 
of which 27,393 were HAI with carbapenem-resist-
ant  E. coli  or  K. pneumoniae) was close to the num-
ber of 33,172 infections with carbapenem-resistant  E. 
coli or K. pneumoniae  recently estimated by Cassini et 
al. using a totally different methodology [19].
The main strengths of this study are its large sample 
size and the use of standardised protocols for data 
collection and validation across participating ACH and 
LCTF. Despite some countries providing less represent-
ative samples, these PPSs as a whole offer a represent-
ative picture of HAI in the EU/EEA, with benchmarks to 
help direct future action in ACH and LCTF in participat-
ing countries.
Conclusion
This study reports, to our knowledge, the most accu-
rate and robust estimates of the total number of HAI in 
healthcare facilities in the EU/EEA to date, and confirms 
that HAI, and AMR in bacteria responsible for HAI, rep-
resent a significant healthcare issue and public health 
challenge for the EU/EEA. Considering that previous 
studies have shown that HAI in ACH alone are respon-
sible for more deaths in the EU/EEA than all other infec-
tious diseases under surveillance at European level 
[1,2], and that our study showed that there are as many 
HAI in LTCF as there are in ACH, more focus needs to be 
dedicated to the prevention of HAI and AMR, through 
the application of available recommendations and 
guidelines [20-25], in both ACH and LTCF.
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